Brief: Onxeo Announces Enrollment Of First Patient In Phase Ib/II Study Revocan

Valerio Therapeutics SA

21/10/2020 18:20

Oct 21 (Reuters) - Onxeo SA  C4X.PA :
    * ONXEO ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE IB/II
STUDY
REVOCAN
    * FIRST RESULTS FROM REVOCAN ARE EXPECTED EARLY 2021
    * FIRST PATIENT IN REVOCAN WAS TREATED AT GUSTAVE ROUSSY,
STUDY
SPONSOR UNDER A CLINICAL RESEARCH AGREEMENT CONCLUDED WITH ONXEO
IN EARLY 2020
    * TWO OTHER INSTITUTIONS ARE EXPECTED TO START RECRUITING
SHORTLY

Source text for Eikon:  ID:nBw4NrGsGa 
Further company coverage:  C4X.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))